These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11803166)

  • 1. Impact of the new K/DOQI guidelines.
    Eknoyan G; Levin NW
    Blood Purif; 2002; 20(1):103-8. PubMed ID: 11803166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meeting the challenges of the new K/DOQI guidelines.
    Eknoyan G
    Am J Kidney Dis; 2003 Jun; 41(5 Suppl):3-10. PubMed ID: 12776308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Contributions of the software La Clé Concerto in the implementation of the NKF-K/DOQI (National Kidney Foundation-Kidney/Dialysis Outcomes Quality Initiative) recommendations for the control of mineral and bone metabolism disorders in the patient with chronic renal failure].
    Ureña P
    Nephrol Ther; 2008 Sep; 4 Spec No 1():9-14, 20-35. PubMed ID: 19031633
    [No Abstract]   [Full Text] [Related]  

  • 4. New clinical practice guidelines for chronic kidney disease: a framework for K/DOQI.
    Patel SS; Kimmel PL; Singh A
    Semin Nephrol; 2002 Nov; 22(6):449-58. PubMed ID: 12430089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Principles and methodology of K/DOQI clinical guidelines].
    Tsukamoto Y
    Clin Calcium; 2004 May; 14(5):689-92. PubMed ID: 15577028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients.
    White CA; Jaffey J; Magner P
    Kidney Int; 2007 Feb; 71(4):312-7. PubMed ID: 17183248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. K/DOQI gets to the heart of managing dyslipidemias in patients with CKD.
    Benner D
    Nephrol Nurs J; 2005; 32(3):337-8. PubMed ID: 16035475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.
    Arenas MD; Alvarez-Ude F; Gil MT; Soriano A; Egea JJ; Millán I; Amoedo ML; Muray S; Carretón MA
    Nephrol Dial Transplant; 2006 Jun; 21(6):1663-8. PubMed ID: 16464885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to K/DOQI guidelines for calcium-based phosphate binders in clinical practice.
    Shastri J; Tran A; Covit A; Pepe J; Sherman RA
    J Ren Nutr; 2008 Jul; 18(4):370-4. PubMed ID: 18558302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease: an overview.
    Bailie GR; Massry SG;
    Pharmacotherapy; 2005 Dec; 25(12):1687-707. PubMed ID: 16305288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. K/DOQI guidelines for bone metabolism and disease in chronic kidney disease patients: some therapeutic implications.
    Uribarri J;
    Semin Dial; 2004; 17(5):349-50. PubMed ID: 15461740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease.
    Kidney Disease Outcomes Quality Initiative (K/DOQI) Group
    Am J Kidney Dis; 2003 Apr; 41(4 Suppl 3):I-IV, S1-91. PubMed ID: 12671933
    [No Abstract]   [Full Text] [Related]  

  • 13. Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients.
    Monge M; Shahapuni I; Oprisiu R; El Esper N; Morinière P; Massy Z; Choukroun G; Fournier A
    Nat Clin Pract Nephrol; 2006 Jun; 2(6):326-36. PubMed ID: 16932454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hypertension, dyslipidemia and cardiovascular risk in chronic renal disease].
    Ravera M; Paoletti E
    Ital Heart J Suppl; 2004 Jun; 5(6):436-44. PubMed ID: 15471148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Outlines of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease].
    Orita H; Akizawa T
    Clin Calcium; 2004 May; 14(5):693-7. PubMed ID: 15577029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis.
    Arenas MD; Alvarez-Ude F; Torregrosa V; Gil MT; Carretón MA; Moledous A; Nuñez C; Devesa R; Albiach B
    J Nephrol; 2007; 20(4):453-61. PubMed ID: 17879212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of calcium and phosphorus metabolism in hemodialysis patients in Tehran Province, Iran.
    Mahdavi-Mazdeh M; Zamyadi M; Norouzi S; Heidary Rouchi A
    Iran J Kidney Dis; 2007 Jul; 1(1):25-8. PubMed ID: 19357440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Executing change in the management of chronic kidney disease: perspectives on guidelines and practice.
    Levin A; Stevens LA
    Med Clin North Am; 2005 May; 89(3):701-9. PubMed ID: 15755474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achieving K/DOQI laboratory target values for bone and mineral metabolism: an uphill battle.
    Al Aly Z; González EA; Martin KJ; Gellens ME
    Am J Nephrol; 2004; 24(4):422-6. PubMed ID: 15308874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relationship between sevelamer HCl and vascular calcification].
    Uemura K; Kakuta T; Saito A
    Clin Calcium; 2007 Mar; 17(3):392-8. PubMed ID: 17339744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.